Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents.
Greiner J, Schrappe M, Claviez A, Zimmermann M, Niemeyer C, Kolb R, Eberl W, Berthold F, Bergsträsser E, Gnekow A, Lassay E, Vorwerk P, Lauten M, Sauerbrey A, Rischewski J, Beilken A, Henze G, Korte W, Möricke A; THROMBOTECT Study Investigators. Greiner J, et al. Among authors: claviez a. Haematologica. 2019 Apr;104(4):756-765. doi: 10.3324/haematol.2018.194175. Epub 2018 Sep 27. Haematologica. 2019. PMID: 30262570 Free PMC article. Clinical Trial.
The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group.
Stanulla M, Dynybil C, Bartels DB, Dördelmann M, Löning L, Claviez A, Schrappe M; ALL-BFM study group. Stanulla M, et al. Among authors: claviez a. Haematologica. 2007 Nov;92(11):1581-2. doi: 10.3324/haematol.10260. Haematologica. 2007. PMID: 18024413 Free article.
Secondary histiocytic sarcoma may cause apparent persistence or recurrence of minimal residual disease in childhood acute lymphoblastic leukemia.
Alten J, Klapper W, Leuschner I, Eckert C, Beier R, Vallo E, Krause M, Claviez A, Vieth S, Bleckmann K, Möricke A, Schrappe M, Cario G. Alten J, et al. Among authors: claviez a. Pediatr Blood Cancer. 2015 Sep;62(9):1656-60. doi: 10.1002/pbc.25523. Epub 2015 Apr 1. Pediatr Blood Cancer. 2015. PMID: 25833113 Review.
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Suttorp M, Schulze P, Glauche I, Göhring G, von Neuhoff N, Metzler M, Sedlacek P, de Bont ESJM, Balduzzi A, Lausen B, Aleinikova O, Sufliarska S, Henze G, Strauss G, Eggert A, Kremens B, Groll AH, Berthold F, Klein C, Groß-Wieltsch U, Sykora KW, Borkhardt A, Kulozik AE, Schrappe M, Nowasz C, Krumbholz M, Tauer JT, Claviez A, Harbott J, Kreipe HH, Schlegelberger B, Thiede C. Suttorp M, et al. Among authors: claviez a. Leukemia. 2018 Jul;32(7):1657-1669. doi: 10.1038/s41375-018-0179-9. Epub 2018 Jun 20. Leukemia. 2018. PMID: 29925908 Clinical Trial.
Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis.
Vogiatzi F, Heymann J, Müller K, Winterberg D, Drakul A, Rösner T, Lenk L, Heib M, Gehlert CL, Cario G, Schrappe M, Claviez A, Bornhauser B, Bourquin JP, Bomken S, Adam D, Frielitz FS, Maecker-Kolhoff B, Stanulla M, Valerius T, Peipp M, Kellner C, Schewe DM. Vogiatzi F, et al. Among authors: claviez a. Blood Adv. 2022 Aug 23;6(16):4847-4858. doi: 10.1182/bloodadvances.2022007364. Blood Adv. 2022. PMID: 35820018 Free PMC article.
164 results